Novo Nordisk A/S / Fundamental strength relative to industry (Mohanram G-Value)

    The G-Value, developed by Mohanram in 2005, is a measure of a fundamental strength for growth companies. According to Mohanram, a low G-Value suggests a higher probability that a stock may be overvalued relative to its growth potential due to hype or overexcitement. The approach is described in detail in Mohanram's 2005 Paper Separating Winners from Losers among LowBook-to-Market Stocks using Financial Statement Analysis.

    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7
    Return on assets (ROA) greater than industry median
    check 23.0% > -4.3%
    Operating cash flow over total assets greater than industry median
    check 25.2% > -13.7%
    Operating cash flow greater than net income
    check $16.28B > $14.88B
    Variance in ROA over the last 5 years less than industry median
    check 0.0% < 1.4%
    Variance in year-over-year sales growth over the last 5 years less than industry median
    check 0.9% < 2.2%
    R&D expenses over total assets greater than industry median
    close 9.4% ≤ 22.6%
    Capex over total assets greater than industry median
    check 12.3% > 1.2%

    G-Value history

    The G-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the G-Value at a specific time in the past.

    6
    6
    6
    6
    5
    6
    6
    6
    5
    5
    5
    6
    5
    6
    6
    6
    5
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    5
    5
    5
    6
    5
    5
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6
    6

    Notifications